Truist Securities Maintains Buy on Boston Scientific, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Boston Scientific (NYSE:BSX) and raised the price target from $86 to $90, indicating confidence in the company's future performance.
July 16, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has maintained its Buy rating on Boston Scientific and raised the price target from $86 to $90, reflecting a positive outlook on the company's future performance.
The raised price target and maintained Buy rating from Truist Securities suggest strong confidence in Boston Scientific's future performance. This is likely to positively impact the stock price in the short term as investors react to the optimistic outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100